MYOCARDIAL-INFARCTION IN NEWLY-DIAGNOSED HYPERTENSIVE MEDICAID PATIENTS FREE OF CORONARY HEART-DISEASE AND TREATED WITH CALCIUM-CHANNEL BLOCKERS

Citation
Sg. Leader et al., MYOCARDIAL-INFARCTION IN NEWLY-DIAGNOSED HYPERTENSIVE MEDICAID PATIENTS FREE OF CORONARY HEART-DISEASE AND TREATED WITH CALCIUM-CHANNEL BLOCKERS, The American journal of medicine, 102(2), 1997, pp. 150-157
Citations number
16
Categorie Soggetti
Medicine, General & Internal
ISSN journal
00029343
Volume
102
Issue
2
Year of publication
1997
Pages
150 - 157
Database
ISI
SICI code
0002-9343(1997)102:2<150:MINHMP>2.0.ZU;2-G
Abstract
PURPOSE: A retrospective cohort analysis of 1,406 newly diagnosed hype rtensive patients, aged 18 to 59, without prior coronary heart disease and initially treated with calcium channel blockers (CCBs) or eight o ther drug regimens was conducted to evaluate the relative risk of acut e myocardial infarction (AMI) among patients on CCBs alone or with a d iuretic. MATERIALS AND METHODS: Administrative claims data from Pennsy lvania's Medicaid program were the data source. Patients were followed up from 1987 to 1994. RESULTS: There was a highly significant trend t owards prescribing CCBs between 1988 and 1991 (P = 0.0001). A total of 67 AMIs occurred, 33 of which were during original drug therapy. Comp ared with those treated with beta blockers, the relative risk of AMI a mong patients treated only with CCBs was 0.49 (95% confidence interval [CI] 0.11 to 2.20). Compared with diuretic therapy, the AMI relative risk associated with CCB therapy was 0.60 (95% CI 0.16 to 2.32) when p atient drug regimen was classified based on the first six prescription s. Several alternative drug regimen classification schemes were tested to evaluate the sensitivity of relative risk of AMI to classification of drug therapy. CONCLUSIONS: The measurement of relative risk of AMI was highly dependent on the study design, including patient selection criteria and classification of patient drug therapy. Previous finding s of elevated risk of AMI from CCB antihypertensive therapy could not be confirmed. (C) 1997 Excerpta Medica, Inc.